Deferasirox
NDC Package 70710-1012-9

The code 70710-1012-9 identifies a specific commercial package of 90 tablet, for suspension in 1 bottle of Deferasirox, labeled by Zydus Pharmaceuticals Usa Inc.. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on May 06, 2021. The current certification is valid through April 07, 2025.

This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710101209. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.